Vitamin D plus K2 acts like a drug, not a supplement

An Italian cardiology team has published a review that argues vitamin D, when given with vitamin K2, acts less like a dietary supplement and more like a low-potency drug. The paper appeared in the International Journal of Molecular Sciences in December 2025. D’Elia and colleagues at the University of Campania Luigi Vanvitelli in Naples pulled together mechanistic, observational, and randomized trial evidence across hypertension, diabetes, heart failure, and vascular calcification. Their case is that the evidence, read as a whole, points toward a pharmacological effect that the major trials missed by design.

The argument starts with the receptor. The vitamin D receptor is not confined to bone and gut. It turns up in endothelial cells, cardiomyocytes, and immune tissue. When the hormonal form 1,25-dihydroxyvitamin D binds, the VDR-RXR complex attaches to vitamin D response elements scattered across an estimated 3 to 5 percent of the human genome. Among the pathways it touches: the renin-angiotensin-aldosterone system, NF-kB-driven inflammation, TGF-beta-mediated fibrosis, and Wnt/beta-catenin signaling in osteoblast differentiation. Those are drug targets. Not micronutrient pathways. The review asks the clinical literature to be read with that distinction in mind.

On the trial evidence, the picture has been stubbornly neutral. The VITAL trial put more than 25,000 people on 2,000 IU of vitamin D3 daily or placebo. Blood pressure and hypertension incidence did not budge. The D2d trial gave 2,423 adults with prediabetes 4,000 IU daily for a median of 2.5 years. The hazard ratio for new diabetes was 0.88, which missed significance (95 percent CI 0.75 to 1.04). DO-HEALTH and Australia’s D-Health Trial enrolled another 40,000 participants between them. Same story: null on cardiovascular and blood pressure endpoints. Meta-analyses from Beveridge et al. across 46 trials and a more recent synthesis by Zhang et al. confirm the pattern.

But D’Elia’s group does not read these nulls as exonerating. They read them as a population problem. Most trial participants started with adequate 25(OH)D levels. Any treatment effect would be diluted from the outset. Subgroup analyses from D2d hint that the signal concentrates in people who begin deficient, meaning serum 25(OH)D below 20 ng/mL (50 nmol/L). Sha et al. looked at nearly 410,000 UK Biobank participants in a 2025 Clinical Nutrition paper and found that severe deficiency (under 30 nmol/L) came with a 10 percent jump in atherosclerotic cardiovascular disease risk and up to 35 percent higher cardiovascular mortality. A separate prospective cohort, the SUN project, tracked 16,437 Spanish adults across a median 12.3 years. The highest quartile of vitamin D had a 30 percent lower risk of incident hypertension than the lowest.

There is an obvious counterargument, and the review does not dodge it: confounding. People with high vitamin D are outdoors more, exercise more, eat differently. That could drive the observational signal without vitamin D doing anything causal. Mendelian randomization studies back this up. The HUNT study analyzed roughly 70,000 Norwegians and could not confirm a causal relationship between genetically predicted vitamin D levels and blood pressure. The observational associations probably reflect reverse causality or residual confounding. The review’s response is that baseline deficiency still matters because the biology operates on a threshold, not a dose-response curve across the full range.

Then comes K2. None of the major vitamin D trials included it. D’Elia et al. argue that was a consequential omission because vitamin K2, specifically menaquinone-7 (MK-7), activates two proteins that decide where calcium ends up. Matrix Gla protein, once carboxylated, stops calcium from settling in artery walls. Osteocalcin directs it into bone. Without enough K2, both proteins sit idle. Vitamin D increases intestinal calcium absorption. If that extra calcium is not steered correctly, the net effect could be harmful. The EVITA trial offers a cautionary data point. It gave 4,000 IU of vitamin D daily for three years to patients with heart failure. The vitamin D group needed more mechanical circulatory support and had more hypercalcemia (6.2 versus 3.1 percent), though the differences were not statistically significant.

The K2-only trials are small but point in one direction. Knapen et al. randomized healthy postmenopausal women to 180 micrograms of MK-7 daily for three years. Arterial elasticity improved and desphospho-uncarboxylated MGP, the inactive form, dropped. In hemodialysis patients, MK-7 slowed coronary artery calcification progression. Elderly men with aortic valve calcification who got MK-7 plus vitamin D3 for 24 months calcified more slowly than the placebo group. A 2025 systematic review covering 14 K2 RCTs reported consistent favourable effects on vascular calcification markers while noting that hard outcome data from an adequately powered trial do not exist.

The pharmacokinetics make co-administration practical. MK-7’s half-life runs about 72 hours against vitamin K1’s 1 to 2 hours. Once-daily dosing works. Both vitamins are fat-soluble and take the same chylomicron route out of the small intestine. Studies have not detected clinically meaningful absorption competition when the two are taken together with a meal that contains fat. D’Elia et al. also flag a dosing-form issue: daily vitamin D produces steadier 25(OH)D levels than large monthly boluses. That might partly account for the nulls in trials such as D-Health, which used 60,000 IU once a month.

The review does not name a recommended combination dose. It accepts the Institute of Medicine’s 20 ng/mL threshold for deficiency but notes that observational data locate possible cardiovascular benefit further up, in the 50 to 70 ng/mL range (125 to 175 nmol/L). Reaching that band usually means at least 2,000 IU of vitamin D3 a day. The 2024 Endocrine Society guidelines have moved on from a universal target. The new framing is: individualize. Baseline status, comorbidities, and what the patient is being treated for shape the target, not a single number.

The authors are explicit about limits. This is a narrative review. It is not systematic. It is not a meta-analysis. Selection bias is inherent in the format and they do not claim otherwise. No new data were collected. The paper had zero external funding. The authors reported no conflicts of interest. The hypothesis that D3 plus K2 co-administration reduces hard cardiovascular events has not faced a large, adequately powered test. Until it does, calling the combination a pharmacological intervention is a mechanistic interpretation, not a settled therapeutic fact.

What the review does, and does well, is pull the evidence into a usable shape. Test first. Dose daily, not monthly. Do not give high-dose vitamin D without K2 to anyone with cardiovascular disease or chronic kidney disease. Whether a molecule is a supplement or a drug is not really about the molecule. It is about whether you deploy it with the diagnostic precision and cofactor attention that pharmacology demands. For someone standing in the supplement aisle, a combined D3 plus K2 product taken daily with food aligns with the weight of mechanistic evidence. The definitive trial has not been run. But the biology has a shape to it, and the shape points toward combination therapy.

References

1. D’Elia S, Bottino R, Carbone A, et al. Modulation of cardiometabolic risk by vitamin D and K2: simple supplementation or real drug? Uncovering the pharmacological properties. Int J Mol Sci 27(1):298. 2025. https://doi.org/10.3390/ijms27010298
2. Sha S, Xie R, Gwenzi T, et al. Real-world evidence for an association of vitamin D supplementation with atherosclerotic cardiovascular disease in the UK Biobank. Clin Nutr 49:118-127. 2025. https://pubmed.ncbi.nlm.nih.gov/41516172/
3. Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380(1):33-44. 2019. https://doi.org/10.1056/NEJMoa1809944
4. Knapen MH, Braam LA, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost 113(5):1135-1144. 2015. https://doi.org/10.1160/TH14-08-0675